Why some die, some survive when equally ill from COVID-19
The Harvard Gazette
Researchers at Harvard-affiliated Massachusetts General Hospital (MGH) have identified the protein “signature” of severe COVID-19, which they describe in a new study published in Cell Reports Medicine.
“We were interested in asking whether we could identify mechanisms that might be contributing to death in COVID-19,” says MGH infectious disease expert Marcia Goldberg, who studies interactions between microbial pathogens and their hosts, and is senior author of the study. “In other words, why do some patients die from this disease, while others who appear to be just as ill survive?”
Share This
The FINANCIAL Researchers at Harvard-affiliated Massachusetts General Hospital (MGH) have identified the protein “signature” of severe COVID-19, which they describe in a new study published in Cell Reports Medicine.
“We were interested in asking whether we could identify mechanisms that might be contributing to death in COVID-19,” says MGH infectious disease expert Marcia Goldberg, who studies interactions between microbial pathogens and their hosts, and is senior author of the study. “In other words, why do some patients die from this disease, while others who appear to be just as ill survive?”
According to Harvard University, in March 2020, when the first patients with symptoms of COVID-19 began arriving at MGH’s emergency department (ED), Goldberg was contacted by her colleague, Michael Filbin, an attending physician and director of Clinical Research at MGH’s ED, and lead author of the study. Filbin and Goldberg had earlier begun collaborating
E-Mail
BOSTON - Researchers at Massachusetts General Hospital (MGH) have identified the protein signature of severe COVID-19, which they describe in a new study published in
Cell Reports Medicine. We were interested in asking whether we could identify mechanisms that might be contributing to death in COVID-19, says MGH infectious disease expert Marcia Goldberg, MD, who studies interactions between microbial pathogens and their hosts, and is senior author of the study. In other words, why do some patients die from this disease, while others who appear to be just as ill survive?
In March 2020, when the first patients with symptoms of COVID-19 began arriving at MGH s emergency department (ED), Goldberg was contacted by her colleague, Michael Filbin, MD, MS, an attending physician and director of Clinical Research at MGH s ED, and lead author of the study. Filbin and Goldberg had earlier begun collaborating with MGH immunologist Nir Hacohen, PhD, to develop methods for study